Story
Intel Could Double in Two Years on Foundry Strength, Melius Analyst Says

Summary
An analyst at Melius Research reiterated a Buy rating on Intel, setting a two-year price target of $165 and suggesting a potential path to $200, driven by the strategic value of the company's foundry business amid a push for domestic AI chip production.
Intel Corp. (INTC) shares could more than double from their current levels, according to an analyst at Melius Research who sees immense value in the chipmaker's burgeoning foundry business. In a note to clients, the firm reiterated its Buy rating and a two-year price target of $165, with analyst Ben Reitzes suggesting that "even $200 over 2 years is on the table."
Sum-of-the-Parts Valuation
The bullish outlook is based on a sum-of-the-parts valuation, which separates Intel's core product business from its manufacturing arm. Reitzes argued that both the foundry and product divisions could each be worth well over $80 per share. The $165 price target reflects a 15% to 20% discount to this combined $200 valuation, implying more than 100% upside from Intel's recent price above $97 per share.
"The AI 'puck' has skated toward Intel's foundry asset, in addition to CPUs in general," Reitzes wrote, as reported by Investing.com. He viewed the company's recent $20 billion stock sale, conducted at $95 a share to fund its foundry expansion, as a sign of management's strong conviction in its strategy.
AdFoundry's Strategic Importance
The analysis frames Intel's foundry operations—which include its facilities, engineers, and intellectual property—as a critical component of U.S. national security. This importance is magnified by the global concentration of advanced semiconductor manufacturing in Taiwan.
Melius Research suggested the foundry unit could eventually be spun off around 2030 to become a "US Foundry National Champion." The note also pointed to a strong list of strategic supporters for Intel's domestic manufacturing ambitions, including the U.S. government, Nvidia, and SoftBank.
Read next
More on Stocks
BOJ Rate Hike Nears, Pitting Japanese Financials Against Exporters
The Bank of Japan is widely expected to raise its key interest rate to a 31-year high this week, a move that is creating a sharp divide in the stock market between beneficiaries like banks and sectors facing pressure, such as exporters.

Genscript Biotech Stock Surges Over 16% on Eli Lilly AI Partnership
Shares in the Hong Kong-listed biotech firm rallied after announcing a collaboration with Eli Lilly's AI-powered drug discovery platform, a move supported by a recent capital raise focused on AI infrastructure.

Volkswagen's Seat Brand Faces Discontinuation Amid Chinese EV Pressure
Volkswagen is reportedly set to phase out its historic Spanish brand, Seat, as part of a major restructuring to combat rising competition from Chinese automakers and focus investment on its profitable, all-electric Cupra marque.

Hong Kong Biotech Sector Shows Stark Divide as Biocytogen, Genscript Post Major Gains
A small group of companies, led by Biocytogen Pharmaceuticals and Genscript Biotech, have delivered substantial one-year returns, highlighting a sharp performance gap within Hong Kong's 52-stock biotech universe where most firms remain unprofitable.